Insmed is developing and investigating treatments for rare lung diseases. Current product candidates utilize proprietary technology designed specifically for delivery of pharmaceuticals to the lung.

Product Pipeline

PreclinicalPhase 1Phase 2Phase 3Commercial
  • ALIS (nontuberculous mycobacterial lung infection) 70%
  • ALIS (chronic Pseudomonas aeruginosa in non-CF bronchiectasis) 50%
  • INS1007 (non-cystic fibrosis bronchiectasis) 30%
  • INS1009 (pulmonary arterial hypertension) 30%
  • Additional proprietary programs 15%